Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,024 across all filing types
Latest filing 2016-05-11 Director's Dealing
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2016-05-11 English
FORM 4 SUBMISSION
Director's Dealing
2016-05-11 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the entry into a material definitive agreement (a Royalty Settlement and Release Agreement), termination of a material definitive agreement, a significant share acquisition by Frost Gamma Investments Trust, and changes in the company's board of directors and senior management, including resignations and new appointments. The document does not contain financial statements or detailed financial analysis but rather reports on corporate governance changes and material agreements. The key elements are changes in control and management, which align with the Board/Management Information category. Therefore, the appropriate classification is MANG (Board/Management Information). The document length (8782 characters) and detailed content support a high confidence in this classification.
2016-05-11 English
10-Q
Interim / Quarterly Report Q1 2016
2016-05-03 English
10-K
Annual Report FY 2015
2016-03-25 English
FORM 4 SUBMISSION
Director's Dealing
2016-03-24 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.